C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/11 (2006.01) A61K 31/7088 (2006.01)
Patent
CA 2685444
The invention relates to oligomeric compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative diseases, including cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
La présente invention concerne les composés oligomériques (oligomères), qui ciblent l'ARNm codant pour la béta caténine dans une cellule, menant à une expression réduite de la béta caténine. La réduction de l'expression de la béta caténine est bénéfique pour un éventail de troubles médicaux, tels que les maladies hyperprolifératives, y compris le cancer. L'invention concerne des compositions thérapeutiques comprenant des oligomères et les procédés pour moduler l'expression de la béta caténine à l'aide desdits oligomères, y compris les procédés de traitement.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Enzon Pharmaceuticals Inc.
Santaris Pharma A/s
LandOfFree
Rna antagonist compounds for the modulation of beta-catenin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rna antagonist compounds for the modulation of beta-catenin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rna antagonist compounds for the modulation of beta-catenin will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1526997